A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2016
This study is evaluating the efficacy of acalabrutinib in combination with rituximab (Arm 1) versus ibrutinib (Arm 2) versus acalabrutinib (Arm 3) for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Epistemonikos ID: f10d68f5bf7cd5a93ab9fd59631462f484aa5dfe
First added on: May 12, 2024